Abstract
Hepatic sarcomatoid carcinoma (HSC) is characterized by its aggressive behavior and poor prognosis. As of now, no universally endorsed standard therapeutic approaches for HSC have been established. Herein, we describe the case of a 60-year-old individual diagnosed with HSC, subsequently presenting with multiple metastases postoperatively. Owing to the pronounced expression of programmed cell death protein 1 (PD-1), the individual was subjected to monotherapy utilizing sintilimab for a duration spanning 12 months. Following this regimen, a synergistic treatment approach comprising both anlotinib and sintilimab was instituted, culminating in an ensuing 11 months of efficacious therapeutic response. Throughout the course of treatment, the patient's quality of life remained satisfactory. This particular therapeutic strategy not merely reinforces the efficacy of PD-1 inhibitors in the realm of HSC management, but more pivotally, suggests that tyrosine kinase inhibitors (TKIs) might counteract resistance to PD-1 antagonists, thus offering a potentially augmented treatment paradigm for HSC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Chen X et al (2022) Safety and efficacy of sintilimab and anlotinib as first line treatment for advanced Hepatocellular Carcinoma (KEEP-G04): a Single-Arm Phase 2 Study. Front Oncol 12:909035
Chi Y et al (2018) Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res 24(21):5233–5238
Chu T et al (2021) Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC. J Thorac Oncol 16(4):643–652
Fukumura D et al (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15(5):325–340
Gao S et al (2020a) Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol 15(5):816–826
Gao Y, Liu P, Shi R (2020b) Anlotinib as a molecular targeted therapy for tumors. Oncol Lett 20(2):1001–1014
Ji W et al (2021) Primary liver sarcomatoid carcinoma: a case series and literature review. J Hepatocell Carcinoma 8:1117–1127
Karavasilis V et al (2008) Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 112(7):1585–1591
Koo HR et al (2008) Radiological and clinical features of sarcomatoid hepatocellular carcinoma in 11 cases. J Comput Assist Tomogr 32(5):745–749
Ma S et al (2022) A retrospective study on the clinical and pathological features of hepatic sarcomatoid carcinoma: Fourteen cases of a rare tumor. Medicine (baltimore) 101(31):e30005
Ren Z et al (2021) Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol 22(7):977–990
Rizzo A, Ricci AD, Brandi G (2020) Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future Oncol 16(32):2587–2589
Santoni M et al (2022) The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit Rev Oncol Hematol 170:103596
Santoni M et al (2023) Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother 72(6):1365–1379
Seddon B et al (2017) Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 18(10):1397–1410
Shen G et al (2018) Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol 11(1):120
Shi D et al (2020) Clinical and imaging characteristics of primary hepatic sarcomatoid carcinoma and sarcoma: a comparative study. BMC Cancer 20(1):977
Shi Y et al. (2022) Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). Cancer Commun (Lond)
Sun Y et al (2016) Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol 9(1):105
Wang QB et al (2012) Clinicopathological characteristics and outcome of primary sarcomatoid carcinoma and carcinosarcoma of the liver. J Gastrointest Surg 16(9):1715–1726
Yamamoto T et al (2014) Carcinosarcoma of the liver: report of a case. Surg Today 44(6):1161–1170
Yi M et al (2019) Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer 18(1):60
Zhang L et al (2020) Sintilimab: a promising anti-tumor PD-1 antibody. Front Oncol 10:594558
Zhang F et al (2022) Three-year follow-up of neoadjuvant programmed cell death protein-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol 17(7):909–920
Funding
The authors declare that no funds, grants, or other support was received during the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
JC and WC contributed to collecting the data and drafting the manuscript. YC and XQ helped design and revise the manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Ethics approval
This is an observational study. The XYZ Research Ethics Committee has confirmed that no ethical approval is required.
Consent to publish
Informed consent was obtained from the patient and her husband.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chen, J., Chen, W., Qu, X. et al. Multi-targeted tyrosine kinase inhibitor reverses resistance to immunotherapy in hepatic sarcomatoid carcinoma. J Cancer Res Clin Oncol 149, 17849–17853 (2023). https://doi.org/10.1007/s00432-023-05491-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-023-05491-7